XLRN - Acceleron Pharm Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-0.09%) AAPL (%) BABA (%) LZB (%) MYOV (%) V (-1.1%) DGAZ (-1.09%) NVDA (%) UGAZ (1.11%) AVGR (%) ATNM (%) AMRN (1.53%) HIIQ (-7.24%) GS (%) GOOGL (%) GOOG (%) GDX (%) FCEL (-0.79%) FB (%) ETHUSD (%) ETCUSD (%) ENG (1%) DIS (%) DHR (-0.68%) DASHUSD (%)

XLRN - Acceleron Pharma Inc...

$43.77 0.39[0.9%]

15 mins delayed data

People also watch :

+Watchlist

Analyst Ratings | Earnings

Previous Close	$43.38	Open	$43.69
Volume	62.4K	Market Cap	2.144B
Yield		Last Dividend

Day

52 Week

CRISPR Therapeutics stock jumps on early...	11/19/19
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potentia...

Biotech Stock Roundup: SLDB Plunges, CEL...	11/13/19
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Edited Transcript of XLRN earnings confe...	11/12/19
Q3 2019 Acceleron Pharma Inc Earnings Call

Celgene & Acceleron Get FDA Nod for ...	11/11/19
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.

How Celgene Added A New Drug To Its Whee...	11/08/19
Shares of Acceleron Pharma popped Friday after the biotech company gained Food and Drug Administration approval for a Celgene-partnered anemia treatme...

Celgene's rare disease drug gets FDA...	11/08/19
Shares of Celgene Corp. [s:celg] rose 0.34% in afternoon trading after the U.S. Food and Drug Administration approved Reblozyl. The drug, which treats...

FDA approves Acceleron's blood disor...	11/08/19
Luspatercept is one of the first treatments for beta thalassemia, a blood disorder being targeted by multiple local companies.

FDA Approves REBLOZYL® (luspatercept-aam...	11/08/19
REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients

Acceleron Announces Luspatercept Present...	11/06/19
– Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept a...

Acceleron Reports Third Quarter 2019 Ope...	11/06/19
- FDA’s review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing -

ANALYST RATINGS

5 analyst ratings (Last 6 months)

60.00 %

Strong Buy + Buy

Price Target (PT)

Hold rating	10/11/19
Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $52.00 to $48.00

Buy rating	09/17/19
Citigroup maintains Buy rating and lowers Price Target from $61.00 to $52.00

Buy rating	09/17/19
Citi maintains Buy rating and lowers Price Target from $61.00 to $52.00

Strong Buy rating	08/06/19
JP Morgan maintains Overweight rating and lowers Price Target from $61.00 to $58.00

Hold rating	05/29/19
and announces Price Target of $54.00

EARNINGS

Date	2019-11-06 (BMO)	Est. (EPS/Rev.)	($0.82)/ 4.44M
Actual (EPS/Rev.)	$-0.86/ $4.21 M	EPS (TTM)	0

TRADERS TRACKING $XLRN

No traders tracking are currently recommending this stock

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.